Moleculin Biotech (MBRX) Proxy Filing summary

Executive summary

• Special Meeting scheduled for April 15, 2026, to address key corporate actions and proposals.

• Board unanimously recommends voting in favor of all proposals presented at the meeting.

• Quorum for the meeting requires representation of one-third of outstanding common stock.

• Proxy materials are available electronically, and multiple voting methods are provided for shareholder convenience.

Voting matters and shareholder proposals

• Proposal 1 seeks approval for issuance of up to 6,367,956 shares upon exercise of warrants issued in a private placement, in compliance with Nasdaq Listing Rule 5635(d).

• Proposal 2 requests approval to amend the Certificate of Incorporation to change the company’s name to Moleculin Inc.

• Proposal 3 allows adjournment of the meeting to solicit additional proxies if needed for Proposals 1 or 2.

• Board recommends voting “FOR” all three proposals.

• Voting can be done in person, by mail, phone, or internet, with detailed procedures for both record and beneficial owners.

Board of directors and corporate governance

• Board and management will be present at the meeting to answer shareholder questions.

• Corporate governance information is accessible on the company’s website and available upon request.

• Inspector of election appointed to tabulate votes; results to be disclosed in a Form 8-K filing.